Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07780669
PHASE3

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

624

Start Date

2026-08-27

Completion Date

2030-03-15

Last Updated

2026-09-09

Healthy Volunteers

No

Interventions

DRUG

GSK5784283

GSK5784283 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Standard of care

Standard of care will be administered.

Locations (2)

GSK Investigational Site

Doral, Florida, United States

GSK Investigational Site

Lake Charles, Louisiana, United States